REG - Silence Therapeutics - Silence Therapeutics Notice of Results

Silence TherapeuticsAnnouncement

01/09/2020 07:01

RNS Number : 5245X
  
Silence Therapeutics PLC
  
01 September 2020
  
 

 
Silence Therapeutics Notice of Results 
 
1 September 2020
 
 
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce its unaudited interim results for the half year ended 30 June 2020, on 14 September 2020. 
 
Iain Ross, Executive Chairman, Dr. Rob Quinn, Chief Financial Officer and Dr. Giles Campion, Head of R&D and Chief Medical Officer will host a webcast and live conference call for analysts and investors at 13:00 BST | 08:00 ET on the day of the results. 
 
Details of the webcast and conference call:
 
Webcast link: https://edge.media-server.com/mmc/p/8yn44oft
 
Dial-in Details:
United Kingdom               08002796619
United States                    18778709135
Conference ID                   7577462
 
 
 
For more information, please contact:
 



Silence Therapeutics plc
Iain Ross, Executive Chairman
Rob Quinn, Chief Financial Officer
 
 


Tel:  +44 (0)20 3457 6900




Investec (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


Tel:  +44 (0) 20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




U.S. IR
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com


 Tel: +1 (443) 213-0505



 
 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NORPPUBWRUPUGQR